Floatz logo

NEPENTHE

Prognosis

Peking University First HospitalSmall moleculeN/AActive
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the Prognosis cohort.

Asset / SponsorPhaseRating
Deng Zhan Sheng Mai
Guangdong Provincial Hospital of Traditional Chinese Medicine
Phase 2/3B
DEXKETOPROFEN
Peking University First Hospital
N/AD
METAMIZOLE
Peking University First Hospital
N/AD

Same molecule, other indications

NEPENTHE is also rated in:

PainDormant
BBB
Indicative ·
77 / 100
View asset →
cancer of unknown primary siteDormant
BBB
Indicative ·
75 / 100
View asset →
chronic pain syndromeDormant
BBB
Indicative ·
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →